Security
Annovis Bio, Inc. · ANVS
ANVSNYSECommon stockCurrentCIK 1477845Updated Nov 2, 2026
Name history
QR Pharma, Inc. · through Mar 15, 2019
ANVS price & chart
Loading TradingView…
NYSE:ANVS on TradingView ↗About the company
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
In the news
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results ↗
The Credibility Filter Wall Street Uses to Sort Biotech Winners ↗
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure
Items 3.01, 7.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A - filed by Empery Asset Management, LP regarding Annovis Bio, Inc.
DEFA14A filing
DEF 14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 17,188,961Source | 14,361,576Source | 22,037,091Source | 21,454,571Source | 5,046,455Source | 16,243,703Source | 26,737,253Source | 7,813,295Source | 21,081,625Source | 13,925,633Source | 10,208,264Source | 44,097,580Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,286,399Source | 12,636,630Source | 18,728,945Source | 17,130,286Source | 3,997,767Source | 14,219,081Source | 22,236,175Source | 3,136,968Source | 19,532,338Source | 10,551,916Source | 5,754,720Source | 42,668,838Source |
| Assets, CurrentUSD | — | — | — | — | — | — | — | 7,813,295Source | — | — | 10,208,264Source | 44,097,580Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,032,797Source | 7,297,876Source | 26,291,709Source | 3,124,124Source | 6,797,339Source | 13,117,645Source | 2,683,366Source | 11,167,323Source | 4,230,375Source | 4,617,987Source | 17,959,110Source | 1,397,122Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 2,019Source | 1,328Source | 4,260Source | 1,948Source | 1,172Source | 2,854Source | 1,948Source | 1,101Source | 2,719Source | 1,414Source | 1,052Source | 816Source |
| Additional Paid in CapitalUSD | 167,023,392Source | 136,047,175Source | 191,871,978Source | 164,935,088Source | 114,594,390Source | 184,433,245Source | 164,438,470Source | 107,970,905Source | 180,552,190Source | 144,155,694Source | 102,507,189Source | 76,659,912Source |
| Retained Earnings (Accumulated Deficit)USD | -153,869,247Source | -128,984,803Source | -196,130,856Source | -146,606,589Source | -116,346,446Source | -181,310,041Source | -140,386,531Source | -111,326,034Source | -163,703,659Source | -134,849,462Source | -110,259,087Source | -33,960,270Source |
| Stockholders' Equity Attributable to ParentUSD | 13,156,164Source | 7,063,700Source | -4,254,618Source | 18,330,447Source | -1,750,884Source | 3,126,058Source | 24,053,887Source | -3,354,028Source | 16,851,250Source | 9,307,646Source | -7,750,846Source | 42,700,458Source |
| Liabilities and EquityUSD | 17,188,961Source | 14,361,576Source | 22,037,091Source | 21,454,571Source | 5,046,455Source | 16,243,703Source | 26,737,253Source | 7,813,295Source | 21,081,625Source | 13,925,633Source | 10,208,264Source | 44,097,580Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,733,797Source | 5,391,376Source | 6,358,709Source | 2,805,124Source | 4,057,339Source | 12,790,645Source | 2,504,366Source | 4,870,015Source | 3,635,375Source | 3,880,987Source | 4,279,110Source | 1,397,122Source |
| Accounts Payable, CurrentUSD | 2,112,026Source | 4,099,414Source | 3,327,138Source | 974,311Source | 3,394,657Source | 5,275,668Source | 1,370,189Source | 4,106,832Source | 2,590,516Source | 2,305,974Source | 1,292,837Source | 928,997Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -17,606,382Source | -5,537,069Source | -28,854,197Source | -24,590,375Source | -56,204,313Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 182,823Source | 499,887Source | 1,797,676Source | 3,836,770Source | 4,628,406Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,685,152Source | -935,785Source | 284,542Source | 1,013,138Source | -2,668,417Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -9,011,624Source | -8,099,164Source | -25,619,703Source | -21,894,604Source | -39,967,304Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,698,367Source | 19,783,423Source | 34,600,125Source | 26,691,800Source | 17,344,331Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,313,257Source | 11,684,259Source | 8,980,422Source | 4,797,196Source | -22,622,973Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 15,286,399Source | 12,636,630Source | 18,728,945Source | 17,130,286Source | 14,219,081Source | 22,236,175Source | 19,532,338Source | 10,551,916Source | 5,754,720Source | 42,668,838Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 1,143,804Source | 1,698,050Source | 2,370,412Source | 1,109,532Source | 1,291,820Source | 1,271,164Source | 4,479,651Source | 6,699,481Source | 6,244,408Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 152,317Source | 135,430Source | 160,233Source | 191,395Source | 137,800Source | 187,612Source | 699,061Source | 331,849Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,262,658Source | -12,638,357Source | -14,820,815Source | -6,220,058Source | -17,606,382Source | -5,537,069Source | -28,854,197Source | -24,590,375Source | -56,204,313Source | — |
| Nonoperating Income (Expense)USD | — | — | 172,317Source | -8,250,746Source | -443,103Source | 51,395Source | 405,800Source | 745,612Source | 841,061Source | 2,104,553Source | -11,169,302Source | — |
| Operating ExpensesUSD | — | — | 7,434,975Source | 4,387,611Source | 14,377,712Source | 6,271,453Source | 18,012,182Source | 6,282,681Source | 29,695,258Source | 26,694,928Source | 45,035,011Source | — |
| Operating Lease, ExpenseUSD | — | — | 24,181Source | 24,344Source | 26,566Source | 24,844Source | 25,886Source | 32,737Source | 100,000Source | 100,000Source | 70,674Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 18,666,797Source | 16,885,946Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 1,999Source | 0Source | 8,385Source | — |
| Share-based Payment Arrangement, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -7,434,975Source | -4,387,611Source | -14,377,712Source | -6,271,453Source | -18,012,182Source | -6,282,681Source | -29,695,258Source | -26,694,928Source | -45,035,011Source | -25,511,279Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -12,638,357Source | — | — | — | — | — | — | -56,204,313Source | -25,328,567Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,262,658Source | -12,638,357Source | -14,820,815Source | -6,220,058Source | -17,606,382Source | -5,537,069Source | -28,854,197Source | -24,590,375Source | -56,204,313Source | -25,328,567Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.37Source | -0.97Source | -0.4Source | -0.32Source | -0.63Source | -0.32Source | -1.4Source | -2.02Source | -6.23Source | -3.1Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.37Source | -0.97Source | -0.4Source | -0.32Source | -0.63Source | -0.32Source | -1.4Source | -2.31Source | -6.23Source | -3.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 19,685,071Source | 12,975,808Source | 37,518,778Source | 19,486,231Source | 27,847,884Source | 17,431,234Source | 20,551,997Source | 12,182,475Source | 9,023,138Source | 8,162,326Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 19,685,071Source | 12,975,808Source | 37,518,778Source | 19,486,231Source | 27,847,884Source | 17,431,234Source | 20,551,997Source | 12,235,444Source | 9,023,138Source | 8,162,326Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 1,143,804Source | 1,698,050Source | 2,370,412Source | 1,109,532Source | 1,291,820Source | 1,271,164Source | 4,479,651Source | 6,699,481Source | 6,244,408Source | 8,995,736Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | 667,898Source | 182,712Source |
| Investment Income, InterestUSD | — | — | 152,317Source | 135,430Source | 160,233Source | 191,395Source | 137,800Source | 187,612Source | 699,061Source | 331,849Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 172,317Source | -8,250,746Source | -443,103Source | 51,395Source | 405,800Source | 745,612Source | 841,061Source | 2,104,553Source | -11,169,302Source | 182,712Source |
| Operating ExpensesUSD | — | — | 7,434,975Source | 4,387,611Source | 14,377,712Source | 6,271,453Source | 18,012,182Source | 6,282,681Source | 29,695,258Source | 26,694,928Source | 45,035,011Source | 25,511,279Source |
| Operating Lease, ExpenseUSD | — | — | 24,181Source | 24,344Source | 26,566Source | 24,844Source | 25,886Source | 32,737Source | 100,000Source | 100,000Source | 70,674Source | 66,802Source |
| Research and Development ExpenseUSD | — | — | 6,291,171Source | 2,689,561Source | 12,007,300Source | 5,161,921Source | 16,720,362Source | 5,011,517Source | 25,215,607Source | 19,995,447Source | 38,790,603Source | 16,515,543Source |
Filing attachments
tm2628596d1_ex99-1.htm · 8-K · 2026-10-30
Exhibit 99.1 ANNOVIS BIO, INC. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE MALVERN, PA - October 30, 2026 - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) t…
Read attachment ↗tm2623272d1_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2623272d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026. ───────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗tm2620172d1_ex99-1.htm · 8-K · 2026-07-10
EX-99.1 2 tm2620172d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each readout Malvern, PA, July 7, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”…
Read attachment ↗tm2615162d1_ex4-1.htm · 8-K · 2026-05-20
EX-4.1 2 tm2615162d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 WARRANT TO PURCHASE COMMON STOCK ANNOVIS BIO, INC. Warrant Shares: [ ] Issue Date: May 21, 2026 ───────────────────────────────────────────────────── THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (th…
Read attachment ↗tm2615162d1_ex99-1.htm · 8-K · 2026-05-20
EX-99.1 5 tm2615162d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants MALVERN, Pa., May 19, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offe…
Read attachment ↗tm2615162d1_ex99-2.htm · 8-K · 2026-05-20
EX-99.2 6 tm2615162d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants MALVERN, Pa., May 20, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritte…
Read attachment ↗